The bioT3 Platform

Ralph V. Boccia, MD, FACP

Video Categories: PMO Interview with the Innovator Series: Volume 9

Dr. Boccia describes the components of the bioT3 platform and its clinical utility in identifying tumor type and actionable targets for therapy.

Related Videos

January 20, 2016

Therapeutic Agents in Clinical Trials

Dr Wainberg and Dr Gerson identify some of the challenges of preclinical models versus clinical trials.

September 2, 2015

Aspirations for the Launch of Ixazomib

Ixazomib may have the potential for great combinability with other drugs, according to Dixie-Lee Esseltine, MD and George Mulligan, PhD. Combination therapy improves compliance, adherence, and quality of life among patients.